Clinical Trials Sponsored by Pulse Therapeutics
Total 6292 results
-
Halozyme TherapeuticsCompletedMetastatic Pancreatic CancerUnited States
-
Eleusis TherapeuticsCompleted
-
Effector TherapeuticsCompletedCastrate-resistant Prostate Cancer (CRPC)United States
-
Sangamo TherapeuticsCompletedIdiopathic Parkinson's DiseaseUnited States
-
Blade TherapeuticsCompleted
-
Therapeutics, Inc.CompletedPlaque PsoriasisUnited States
-
United TherapeuticsCompletedPulmonary Arterial HypertensionKorea, Republic of, United States, Australia, Austria, Taiwan, China, Israel, Canada, India, Germany, Singapore, United Kingdom, Brazil, Italy, Netherlands, Argentina, Sweden, Chile, Denmark, France, Greece, Mexico, Poland
-
Corcept TherapeuticsCompletedCushing's SyndromeNetherlands, United States, Hungary, Italy, United Kingdom
-
Sangamo TherapeuticsCompletedHIV Infection | HIVUnited States
-
Corcept TherapeuticsCompleted
-
Celldex TherapeuticsCompletedSquamous Cell Carcinoma of the Head and NeckUnited States
-
Aprea TherapeuticsCompletedProstatic Neoplasms | Hematologic NeoplasmsSweden
-
Windtree TherapeuticsTerminatedRespiratory Distress SyndromeCanada, United States, Chile, Poland
-
Proteon TherapeuticsCompleted
-
BioMimetic TherapeuticsUnknownAnkle and Hindfoot Arthrodesis
-
PTC TherapeuticsWithdrawnDuchenne Muscular Dystrophy
-
Promethera TherapeuticsCompletedUrea Cycle Disorders | Crigler Najjar SyndromeBelgium
-
Cyclerion TherapeuticsCompletedHealthyUnited States
-
Akebia TherapeuticsCompletedHepatic ImpairmentUnited States
-
Akebia TherapeuticsCompletedDrug Interaction PotentiationCanada
-
Akebia TherapeuticsCompleted
-
Akebia TherapeuticsCompletedPharmacokinetics | Drug Interaction PotentiationCanada
-
Corcept TherapeuticsCompletedHealthyUnited Kingdom
-
Intarcia TherapeuticsTerminatedDiabetes Mellitus, Type 2United States, Canada
-
Halozyme TherapeuticsCompletedType 1 Diabetes MellitusUnited States
-
BioMimetic TherapeuticsCompletedFull Thickness Rotator Cuff TearCanada
-
Amicus TherapeuticsApproved for marketingPhysician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry DiseaseFabry DiseaseUnited States, Australia
-
Placon TherapeuticsUnknownBreast Neoplasms | Prostatic Neoplasms | Pancreatic Neoplasms | Ovarian NeoplasmsUnited States
-
United TherapeuticsCompleted
-
Agile TherapeuticsCompleted
-
BioMimetic TherapeuticsCompletedArthritis | Osteoarthritis | Rheumatoid Arthritis | Degenerative Joint Disease | Congenital DeformityUnited States, Canada
-
Heron TherapeuticsCompleted
-
Akebia TherapeuticsCompleted
-
Therapeutics, Inc.CompletedPlaque PsoriasisUnited States
-
Therapeutics, Inc.CompletedPlaque PsoriasisUnited States
-
Halozyme TherapeuticsCompleted
-
Akebia TherapeuticsWithdrawnAnemia | Dialysis-Dependent Chronic Kidney DiseaseUnited States
-
Amicus TherapeuticsCompletedFabry DiseaseAustralia, Brazil
-
Amicus TherapeuticsCompletedFabry DiseaseUnited States
-
Therapeutics, Inc.Completed
-
Acorda TherapeuticsTerminatedRefractory EpilepsyUnited States
-
Fate TherapeuticsTerminatedMetabolic DisordersUnited States
-
Fate TherapeuticsTerminatedA Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic MalignanciesHematologic MalignanciesUnited States
-
Amicus TherapeuticsTerminatedFabry DiseaseUnited Kingdom, United States, Australia, Brazil, France
-
Cristal TherapeuticsCompletedCancer | Metastatic Cancer | Solid TumorsNetherlands, Belgium
-
Acorda TherapeuticsCompleted
-
Corcept TherapeuticsCompleted
-
Amicus TherapeuticsCompletedFabry DiseaseFrance, United Kingdom